Contact Us | Log In
Search
Sensex: 31138.2 -152.50 Gold: Rs.28753.00
Nifty: 9574.95 -55.05 Silver: Rs.38510.00
You are here: IndiaNotes >> Research & Analysis >> IPOs
IPOs
Latest IPO ArticlesView All
GTPL Hathway IPO: Rudra Shares remains 'Neutral' on cut throat competition
Rudra Shares and Stock Brokers | Published: 21 Jun 2017
Taking into consideration, cut throat competition, entry of New players at competitive prices, weak performance of cable industry in past years & forthcoming JIO in this particular industry may impact...
GTPL Hathway IPO: Valuation looks expensive at current level; Avoid
Hem Securities | Published: 21 Jun 2017
According to Hem Securities, recent considerations with TRAI might adversely affect GTPL Hathway's business, results of operation and financial condition. At price band of Rs 167-170, company is bringing the...
Jainam Research recommend to 'Avoid' the GTPL Hathway IPO
Jainam Research | Published: 21 Jun 2017
Jainam Research are citing GTPL Hathway's high capital intensive nature of business, highly competitive industry, dependency on broadcasters, inconsistency in generation of net profit in last 5 years.
CDSL IPO: Issue price valuations appear reasonable; Way2wealth recommend to 'Subscribe'
Way2wealth | Published: 19 Jun 2017
CDSL is a play on increasing financial literacy, financial services penetration and secular growth story of securities markets in India. At the upper band of the offer price of Rs149,...
CDSL IPO looks an attractive issue; HEM Securities recommend to 'Subscribe'
Hem Securities | Published: 19 Jun 2017
At price band of Rs 145-149 ,co is bringing the issue at p/e multi-ple of around 18 on FY17 Eps. Co with its sound fundamentals looks attractive issue. Hence HEM...
Eris Lifesciences (IPO) is Strong on B2D
Punit Jain | Published: 19 Jun 2017
While the IPO is an exit opportunity for some investors, it empowers Eris for the next phase of growth by providing visibility and prestige, and the ability to raise fresh...
Central Depository Services IPO: Rudra Shares recommend to 'Subscribe' to the issue
Rudra Shares and Stock Brokers | Published: 19 Jun 2017
CDSL has put up a great show in financial performance. Companies total revenue grew at a CAGR of 13.33%& PAT grew at a CAGR of 21.96%. In addition to this...
Central Depository Services IPO: Subscribe on attractive pricing - Nirmal Bang
Nirmal Bang | Published: 19 Jun 2017
At Upper band of Rs. 149, CDSL is offered at 12.6x EV/EBITDA of FY17 earnings and 18.2x PE, which looks attractive. Thus, Nirmal Bang recommend subscribing to the issue.
Central Depository Services IPO: Subscribe to the issue with long term perspective
SPA Securities | Published: 19 Jun 2017
At the upper end of the price band, the stock is available at P/E of 18.0x based on FY17 earnings, which is reasonable considering strong parentage, debt free balance sheet,...
Central Depository Services IPO: Sound fundamentals looks attractive; Susbscribe
Hem Securities | Published: 19 Jun 2017
At price band of Rs 145-149, the company is bringing the issue at p/e multiple of around 18 on FY17 EPS. With its sound fundamentals the issue looks attractive. Hence...
Eris Lifesciences IPO: Rudra Shares are 'Neutral' on this IPO
Rudra Shares and Stock Brokers | Published: 19 Jun 2017
Though the company financials are healthy, but major revenue of the company comes from its top 10 brands accounting to 74% in India. Considering the cut throat competition in the...
Intraday Derivatives Call: Buy BANKNIFTY 22JUN 23500 CE above 95 with stop-loss 65
Nirmal Bang | Published: 16 Jun 2017
Technically the index has been moving in a higher top and higher bottom formation, indicating positive bias. The 23500 CE has the highest OI indicating that the index is now...
Eris Lifesciences IPO: Subscribe to the issue from a long term perspective
SPA Securities | Published: 16 Jun 2017
At the issue price, the company is valued at a FY17P/E of 34.3. With present capacity utilization at ~30% and specialty segments growing at a consistent rate, company expects to...
Jainam Research recommend to 'subscribe' to the Eris Lifesciences IPO
Jainam Research | Published: 15 Jun 2017
According to Jainam Research, the company is focusing on high margin therapeutic areas of cardiovascular, anti-diabetics, vitamins, gastroenterology & anti-infectives, prime focus is on metro cities and class 1 towns in India.
Tejas Networks IPO: Subscribe to the issue with long term perspective
SPA Securities | Published: 14 Jun 2017
At the upper end of the price band, the stock is available at P/E of 20.5x based on FY19E earnings, which is reasonable considering immense growth potential in India and...
Eris Lifescience IPO: HEM Securities recommend to 'Subscribe' on issue
Hem Securities | Published: 13 Jun 2017
According to Hem Securities, at price band of Rs 600-603, company is bringing the issue at p/e multiple of around 34.05-34.22 on FY17 Eps of Rs 17.62/share. Its strong financial...
Long term investors may subscribe for Eris Lifescience IPO - SMC
SMC | Published: 13 Jun 2017
At upper price band of Rs.603 EPS and P/E of FY2017 are Rs. 17.61and 34.25 multiple respectively and at a lower price band of Rs. 600, P/E multiple is 34.08....
Tejas Networks IPO: Hem Securities recommend to subscribe to the issue for long term
Hem Securities | Published: 13 Jun 2017
According to Hem Securities, at price band of Rs 250-257, company is bringing the issue at p/e multiple of around 29 on FY17 Eps. Although company's business model looks quite...
Long term investors may opt for the Tejas Networks IPO - SMC
SMC | Published: 12 Jun 2017
Considering the P/E valuation on the upper end of the price band of Rs. 257, the stock is priced at pre issue P/E of 29.28x on its FY17 EPS of...
Jainam Wealth recommend 'Avoid' on the Tejas Networks IPO
Jainam Research | Published: 12 Jun 2017
Considering high working capital intensive nature, 58.81% of revenue contributed from top 5 clients, and 45.12% revenue contributed from PSU customers in India among others, Jainam are recommending investors to avoid the IPO.
View All